Hall PS, Swinson D, Cairns DA, et al. - This multicenter, noninferiority, open-label randomized trial (GO2 randomized clinical trial) was undertaken to optimize chemotherapy dosing among older and/or frail patients suffering from advanced gastroesophageal cancer, and to assess baseline geriatric assessment as an instrument for treatment decision-making. In this study in the United Kingdom, patients were selected for whom full-dose combination chemotherapy was considered not-appropriate due to advanced age and/or frailty. Two randomizations were conducted: CHEMO-INTENSITY compared oxaliplatin/capecitabine at Level A (oxaliplatin 130 mg/m ² on day 1, capecitabine 625 mg/m ² twice daily on days 1-21, on a 21-day cycle), Level B (doses 0.8 times A), or Level C (doses 0.6 times A). Alternatively, if the patient and clinician admitted the indication for chemotherapy was uncertain, the patient could rather enter CHEMO-BSC, comparing Level C vs best supportive care. In this phase 3 randomized clinical trial with 559 patients with advanced gastroesophageal cancer, a better patient experience was shown to be conferred by reduced-intensity chemotherapy without significantly compromising cancer control and thus it is recommended to be considered for older and/or frail patients. Results also revealed that chemotherapy utility can be predicted by baseline geriatric assessment but this tool failed to identify a group benefiting from higher-dose treatment.